BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
Indoco Remedies Ltd.'s Q3 FY22 earnings missed our estimates on account of lower profit share realisation from Brinzolamide and reduced demand for paracetamol in the Europe given the sharp increase in product prices.
Indoco Remedies' India business is broadly tracking management guidance of Rs 8 billion plus revenues; however, the regulated market business was hit by shipment delays due to container unavailability, raw material price inflation and reduced demand for key products (like paracetamol), and thus trailed below our expectations.
We believe the issues are transitionary and expect a rebound in FY23. Our FY22/23E earnings per share is reset by down 10%/down 7% to factor in the nine months-FY22 performance.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
